Zylox-Tonbridge Medical Technology and GL Capital will jointly invest approximately HK$1.48bn ($189m)in LifeTech Scientific, with the former also seeking a potential merger between the two medical device manufacturers.
The investment marks a significant step toward creating an integrated platform for vascular and structural heart interventions in China.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will proceed via GL Lighthouse Two Investment, an entity 60% owned by Zylox-Tonbridge through an approximate HK$889m commitment.
Under the terms of the transaction, Lighthouse Two will subscribe for newly issued shares representing around 16.7% of LifeTech’s enlarged share capital.
In an associated transaction, GL Capital will purchase 39.8 million newly issued shares in Zylox-Tonbridge at HK$22 per share, equivalent to roughly 10.8% of the company’s enlarged share capital.
The subscription price is 13.5% above the closing price on the announcement date and represents a 15.4% premium to the preceding five-day average closing price.
Zylox-Tonbridge plans to use the proceeds for international commercial growth and potential future investments in LifeTech.
Zylox-Tonbridge chairman Dr Jonathon Zhong Zhao said: “With our established operating capabilities and expanding global presence, we see significant opportunities to capture synergies, strengthen our competitiveness and advance our growth as a global medical technology company.”
The transaction unites Zylox-Tonbridge’s peripheral vascular and neurovascular operations with LifeTech’s aortic and structural heart businesses.
During the first half of 2026, the company achieved a 349.3% year-on-year (YoY) revenue increase from markets outside Mainland China.
In 2025, LifeTech generated approximately 400m yuan from international markets, up around 14.4% year on year and representing near 30% of its total revenue, with Asia and Europe serving as primary contributors.
Its portfolio features an iron-based bioabsorbable material technology platform.
Zylox-Tonbridge, which markets devices through Tonbridge Medical and Zylox Medical, held 69 Chinese regulatory approvals by August 2026 and supplies over 3,500 domestic hospitals.
